MorphoSys AG
ISIN: DE0006632003 | Ticker: MOR
MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and delivery of innovative cancer medicines.
Our ambition is to redefine how cancer is treated. As a commercial-stage biopharmaceutical company, we are driven by the urgency to deliver groundbreaking medicines, aspiring to give more life for people with cancer.
1992
Served areaWorldwide
Headcount732
HeadquartersSemmelweisstr. 7, 82152 Planegg – Germany
| Date | Trading entity / Person | Association | Trade type | Volume | Average price |
|---|---|---|---|---|---|
| 30.11.22 | Reissner, Thomas | Supervisory board | Buy | 4,186.00 € | 30.11.22 |
| 30.11.22 | Reissner, Thomas | Supervisory board | Buy | 2,698.00 € | 30.11.22 |
| 30.11.22 | Reissner, Thomas | Supervisory board | Buy | 7,479.00 € | 30.11.22 |
| 30.11.22 | Reissner, Thomas | Supervisory board | Buy | 13,800.00 € | 30.11.22 |
| 29.11.22 | Reissner, Thomas | Supervisory board | Buy | 5,000.00 € | 29.11.22 |
| 29.11.22 | Reissner, Thomas | Supervisory board | Buy | 8,100.00 € | 29.11.22 |
| 28.11.22 | Vermeylen, Krisja | Supervisory board | Buy | 14,860.00 € | 28.11.22 |
| 21.11.22 | Cluzel, Dr. Marc | Supervisory board | Buy | 29,922.20 € | 21.11.22 |
| 11.01.22 | C&F Consulting EURL | Close relation | Buy | 46,088.85 € | 11.01.22 |
| 30.07.21 | Peter, Rene | Other | Buy | 380.00 € | 30.07.21 |
| 30.07.21 | Vermeylen, Krisja | Supervisory board | Buy | 16,538.66 € | 30.07.21 |
34,231,943
IPOMarch 9, 1999
Stock exchange(s)Frankfurt Stock Exchange